Results 81 to 90 of about 31,032 (201)

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells

open access: yesBMC Cancer, 2011
Background Aromatase inhibitors (AI) that inhibit breast cancer cell growth by blocking estrogen synthesis have become the treatment of choice for post-menopausal women with estrogen receptor positive (ER+) breast cancer.
Sabnis Gauri   +6 more
doaj   +1 more source

Letrozole protects against cadmium-induced inhibition of spermatogenesis via LHCGR and Hsd3b6 to activate testosterone synthesis in mice

open access: yesReproductive Biology and Endocrinology, 2022
The heavy metal cadmium is proposed to be one of the environmental endocrine disruptors of spermatogenesis. Cadmium-induced inhibition of spermatogenesis is associated with a hormone secretion disorder.
Yao Yao   +7 more
doaj   +1 more source

The Relationship Between Polycystic Ovary Syndrome (PCOS) and Depression

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder, frequently accompanied by psychological comorbidities including depression. The aim of this narrative review is to summarise the latest research regarding potential contributors to and underpinning mechanisms of this relationship.
Asimina I. Karampela, Maralyn Druce
wiley   +1 more source

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. [PDF]

open access: yes, 2014
BackgroundSince PI3K/AKT/mTOR pathway activation diminishes the effects of hormone therapy, combining aromatase inhibitors (anatrozole) with mTOR inhibitors (everolimus) was investigated.Patients and methodsWe evaluated anastrozole and everolimus in 55 ...
Atkins, Johnique T   +13 more
core   +3 more sources

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis

open access: yesAdvanced Science, Volume 13, Issue 13, 3 March 2026.
This work introduces a study that identifies HMGCR as a novel target in TNBC and develops a light‐gated PROTAC nanomedicine. Upon irradiation, this agent selectively degrades HMGCR, reprogramming lipid metabolism to induce ferroptosis and potent antitumor immunity, thereby significantly enhancing photoimmunotherapy efficacy.
Tong Su   +18 more
wiley   +1 more source

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer [PDF]

open access: yes, 2012
PMCID: PMC3446380This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided ...
A Borg   +48 more
core   +5 more sources

Letrozole versus

open access: yesMiddle East Fertility Society Journal, 2016
Objective: To evaluate the efficacy of letrozole in the endometrial preparation of vitrified–warmed embryo transfer cycles and to compare it to the hormonal preparation with estradiol valerate and progesterone study.
Hoda Sibai   +2 more
doaj   +1 more source

Letrozole Potentiates Mitochondrial and Dendritic Spine Impairments Induced by β Amyloid

open access: yesJournal of Aging Research, 2013
Reduced estrogens, either through aging or postsurgery breast cancer treatment with the oral nonsteroidal aromatase inhibitor letrozole, are linked with declined cognitive abilities.
P. K.-Y. Chang   +3 more
doaj   +1 more source

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

open access: yesBreast Cancer Research, 2020
Background The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer.
Swaathi Jayaraman   +21 more
doaj   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

open access: yesMedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy